Analysts’ Recent Ratings Updates for Moderna (MRNA)

Moderna (NASDAQ: MRNA) recently received a number of ratings updates from brokerages and research firms:

• 10/9/2026 – Moderna had its price target raised by Bank of America Corporation from $170.00 to $200.00. They now have a “neutral” rating on the stock.
• 10/8/2026 – Moderna had its price target raised by Evercore Inc from $50.00 to $80.00.
• 10/7/2026 – Moderna had its price target raised by Morgan Stanley from $89.00 to $95.00. They now have an “equal weight” rating on the stock.
• 9/30/2026 – Moderna was downgraded by Citigroup Inc. from “neutral” to “sell”. They now have a $80.00 price target on the stock, up from $60.00.
• 9/25/2026 – Moderna had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 9/23/2026 – Moderna was upgraded by Singular Research to “hold”.
• 9/22/2026 – Moderna had its “neutral” rating reaffirmed by UBS Group AG.
• 9/11/2026 – Moderna had its price target raised by Berenberg Bank from $45.00 to $100.00. They now have a “hold” rating on the stock.
• 9/9/2026 – Moderna had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/3/2026 – Moderna was given a new $81.00 price target by UBS Group AG.
• 9/3/2026 – Moderna was downgraded by UBS Group AG from “hold” to “sell”.
• 9/3/2026 – Moderna was downgraded by Rothschild & Co Redburn from “neutral” to “sell”. They now have a $81.00 price target on the stock, up from $40.00.
• 8/28/2026 – Moderna was upgraded by CLSA to “outperform”.
• 8/28/2026 – Moderna is now covered by Deutsche Bank Aktiengesellschaft. They set a “hold” rating and a $125.00 price target on the stock.
• 8/28/2026 – Moderna is now covered by William Blair. They set an “outperform” rating on the stock.
• 8/28/2026 – Moderna was upgraded by Bradesco Corretora to “outperform”.
• 8/28/2026 – Moderna was upgraded by Argus from “hold” to “buy”. They now have a $180.00 price target on the stock.
• 8/25/2026 – Moderna was upgraded by Wolfe Research from “underperform” to “peer perform”.
• 8/24/2026 – Moderna had its price target raised by Barclays PLC from $48.00 to $125.00. They now have an “equal weight” rating on the stock.
• 8/21/2026 – Moderna had its price target raised by JPMorgan Chase & Co. from $40.00 to $77.00. They now have an “underweight” rating on the stock.
• 8/20/2026 – Moderna had its price target raised by UBS Group AG from $50.00 to $150.00. They now have a “neutral” rating on the stock.
• 8/20/2026 – Moderna had its price target raised by Piper Sandler from $77.00 to $167.00. They now have an “overweight” rating on the stock.
• 8/20/2026 – Moderna had its price target raised by Morgan Stanley from $39.00 to $89.00. They now have an “equal weight” rating on the stock.
• 8/19/2026 – Moderna had its “neutral” rating reaffirmed by Morgan Stanley.
• 8/19/2026 – Moderna had its price target raised by The Goldman Sachs Group, Inc. from $67.00 to $120.00. They now have a “neutral” rating on the stock.
• 8/19/2026 – Moderna had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $130.00 price target on the stock.
• 8/19/2026 – Moderna was given a new $135.00 price target by Loop Capital.
• 8/19/2026 – Moderna had its “buy” rating reaffirmed by Brookline Capital Markets.
• 8/19/2026 – Moderna had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $150.00 price target on the stock, up from $60.00.
• 8/19/2026 – Moderna was upgraded by Bank of America Corporation from “underperform” to “neutral”. They now have a $170.00 price target on the stock, up from $40.00.
• 8/19/2026 – Moderna was upgraded by William Blair from “market perform” to “outperform”.

Insider Buying and Selling

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 118,882 shares of company stock valued at $16,862,280. Company insiders own 10.80% of the company’s stock.

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.